We are live on
!
Find out more
SGP
SpyGlass Pharma
SGP
SGP
35 hedge funds and large institutions have $655M invested in SpyGlass Pharma in 2026 Q1 according to their latest regulatory filings, with 35 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
35
Holding in Top 10
3
Calls
–
Puts
–
Top Buyers
| 1 | +$216M | |
| 2 | +$199M | |
| 3 | +$67.3M | |
| 4 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$56.8M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$19M |
Top Sellers
No sellers this quarter
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Goldman Sachs
New York
| $500K |
|
|||
27
State Street
Boston,
Massachusetts
| $447K |
|
|||
28
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $308K |
|
|||
29
Squarepoint
New York
| $202K |
|
|||
|
VGA
30
Vanguard Global Advisers
Malvern,
Pennsylvania
| $128K |
|
|||
31
Morgan Stanley
New York
| $108K |
|
|||
|
VPM
32
Vanguard Portfolio Management
Malvern,
Pennsylvania
| $95.3K |
|
|||
33
UBS Group
Zurich,
Switzerland
| $11.8K |
|
|||
34
Barclays
London,
United Kingdom
| $3.63K |
|
|||
35
Royal Bank of Canada
Toronto,
Ontario, Canada
| $2K |
|